Mesoblast (MESO) Consolidated Net Income (2014 - 2023)
Mesoblast (MESO) posted Consolidated Net Income of -$21.9 million for Q2 2023, down 18.14% sequentially from -$18.6 million in Q1 2023, and down 2.41% YoY from -$22.5 million in Q2 2022.
Mesoblast (MESO) Consolidated Net Income (2014 - 2023) Analysis & Trends
Mesoblast has reported Consolidated Net Income for 10 years, with the latest figure at -$21.9 million in Q2 2023.
- Quarterly Consolidated Net Income fell 2.41% year-over-year to -$21.9 million in Q2 2023, while the trailing twelve-month figure through Dec 2024 was -$21.9 million (up 66.22% YoY) and the FY2025 annual result came in at -$102.1 million, down 16.13% from the prior year.
- Consolidated Net Income eased to -$21.9 million in Q2 2023 per MESO's latest filing, from -$18.6 million in the prior quarter.
- Over five years, Consolidated Net Income peaked at -$3.6 million in Q3 2019 and troughed at -$29.4 million in Q2 2020.
- A 5-year average of -$21.1 million and a median of -$22.2 million in 2019 frame the typical range for Consolidated Net Income.
- The sharpest annual moves came in 2019 and 2020: Consolidated Net Income jumped 81.09% in 2019, then plunged 570.44% in 2020.
- Over 5 years, Consolidated Net Income stood at -$22.3 million in 2019, then decreased by 15.46% to -$25.8 million in 2020, then slipped by 0.38% to -$25.9 million in 2021, then increased by 5.61% to -$24.4 million in 2022, then gained by 10.22% to -$21.9 million in 2023.
- According to Business Quant data, Consolidated Net Income over the past three periods registered -$21.9 million, -$18.6 million, and -$24.4 million for Q2 2023, Q1 2023, and Q4 2022 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Mesoblast | 2.01 Bn | 1.87 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -21.92 Mn |
| Mar 31, 2023 | -18.55 Mn |
| Dec 31, 2022 | -24.42 Mn |
| Sep 30, 2022 | -16.83 Mn |
| Jun 30, 2022 | -21.40 Mn |
| Mar 31, 2022 | -21.26 Mn |
| Dec 31, 2021 | -25.87 Mn |
| Sep 30, 2021 | -22.58 Mn |
| Jun 30, 2021 | -22.00 Mn |
| Mar 31, 2021 | -26.42 Mn |
| Dec 31, 2020 | -25.77 Mn |
| Sep 30, 2020 | -23.81 Mn |
| Jun 30, 2020 | -29.35 Mn |
| Mar 31, 2020 | -13.31 Mn |
| Dec 31, 2019 | -22.32 Mn |
| Sep 30, 2019 | -3.55 Mn |
| Jun 30, 2019 | -17.55 Mn |
| Mar 31, 2019 | -22.77 Mn |
| Dec 31, 2018 | -21.74 Mn |
| Sep 30, 2018 | -18.79 Mn |